Intriguingly, immunophenotypically defined HSCs show robust Cxcl9 and Cxcl10 gene expression, both targets of IFN-γ pathway activation, when neither is secreted by AML blasts. The gene discussed is CXCL9; the disease is acute myeloid leukemia.